263 related articles for article (PubMed ID: 16519808)
1. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.
Chaffer CL; Thomas DM; Thompson EW; Williams ED
BMC Cancer; 2006 Mar; 6():53. PubMed ID: 16519808
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
4. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
[TBL] [Abstract][Full Text] [Related]
7. Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.
Qiao L; Dai Y; Gu Q; Chan KW; Ma J; Lan HY; Zou B; Rocken C; Ebert MP; Wong BC
Cancer Lett; 2008 Sep; 268(2):260-71. PubMed ID: 18477501
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
9. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
Takashima T; Fujiwara Y; Hamaguchi M; Sasaki E; Tominaga K; Watanabe T; Oshitani N; Higuchi K; Arakawa T
Oncol Rep; 2005 Apr; 13(4):601-6. PubMed ID: 15756430
[TBL] [Abstract][Full Text] [Related]
10. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
11. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
13. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells.
Clay CE; Namen AM; Atsumi G; Trimboli AJ; Fonteh AN; High KP; Chilton FH
J Investig Med; 2001 Sep; 49(5):413-20. PubMed ID: 11523697
[TBL] [Abstract][Full Text] [Related]
14. EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
Chbicheb S; Yao X; Rodeau JL; Salamone S; Boisbrun M; Thiel G; Spohn D; Grillier-Vuissoz I; Chapleur Y; Flament S; Mazerbourg S
Biochem Pharmacol; 2011 May; 81(9):1087-97. PubMed ID: 21338579
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
Yang YC; Tsao YP; Ho TC; Choung IP
Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
[TBL] [Abstract][Full Text] [Related]
17. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
19. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
20. HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas.
Théoleyre S; Mottier S; Masson D; Denis MG
Biochem Biophys Res Commun; 2010 Apr; 394(3):453-8. PubMed ID: 19951697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
